@article{15a00badae304cf99e28bbdfc4500807,
title = "P-selectin is a nanotherapeutic delivery target in the tumor microenvironment",
abstract = "Disseminated tumors are poorly accessible to nanoscale drug delivery systems because of the vascular barrier, which attenuates extravasation at the tumor site. We investigated P-selectin, a molecule expressed on activated vasculature that facilitates metastasis by arresting tumor cells at the endothelium, for its potential to target metastases by arresting nanomedicines at the tumor endothelium. We found that P-selectin is expressed on cancer cells in many human tumors. To develop a targeted drug delivery platform, we used a fucosylated polysaccharide with nanomolar affinity to P-selectin. The nanoparticles targeted the tumor microenvironment to localize chemotherapeutics and a targeted MEK (mitogen-activated protein kinase kinase) inhibitor at tumor sites in both primary and metastatic models, resulting in superior antitumor efficacy. In tumors devoid of P-selectin, we found that ionizing radiation guided the nanoparticles to the disease site by inducing P-selectin expression. Radiation concomitantly produced an abscopal-like phenomenon wherein P-selectin appeared in unirradiated tumor vasculature, suggesting a potential strategy to target disparate drug classes to almost any tumor.",
author = "Yosi Shamay and Moshe Elkabets and Hongyan Li and Janki Shah and Samuel Brook and Feng Wang and Keren Adler and Emily Baut and Maurizio Scaltriti and Jena, {Prakrit V.} and Gardner, {Eric E.} and Poirier, {John T.} and Rudin, {Charles M.} and Jos{\'e} Baselga and Adriana Haimovitz-Friedman and Heller, {Daniel A.}",
note = "Funding Information: We would like to thank the following core facilities at MSKCC: Molecular Cytology, Electron Microscopy, Small Animal Imaging, and Antitumor Assessment. We would like to thank N. Lampen for assistance with electron microscopy. We would also like to thank J. Budhathoki-Uprety, R. Williams, J. Harvey, D. Roxbury, T. Galassi, J. Humm, and C. Horoszko for helpful discussions. This work was supported by the NIH Director's New Innovator Award (DP2-HD075698), the Cancer Center Support Grant (P30-CA008748), the Experimental Therapeutics Center, Mr. William H. Goodwin and Mrs. Alice Goodwin and the Commonwealth Foundation for Cancer Research, the Alan and Sandra Gerry Metastasis Research Initiative, the Imaging and Radiation Sciences Program, Cycle for Survival, the Louis V. Gerstner Jr. Young Investigator's Fund, the Honorable Tina Brozman Foundation for Ovarian Cancer Research, the Anna Fuller Fund, the Frank A. Howard Scholars Program, and the Center for Molecular Imaging and Nanotechnology at MSKCC. M.E. is an International Sephardic Education Foundation postdoctoral fellow. J.B. has consulted for Novartis Pharmaceuticals and serves on the board of Infinity Pharmaceuticals. C.M.R. has been a paid consultant regarding oncology drug development with Bristol-Myers Squibb, Celgene, Medivation, and Novartis. Y.S. and D.A.H. have a pending patent for the targeted nanoparticle technology. Publisher Copyright: {\textcopyright} 2016, American Association for the Advancement of Science. All rights reserved.",
year = "2016",
month = jun,
day = "29",
doi = "10.1126/scitranslmed.aaf7374",
language = "English (US)",
volume = "8",
journal = "Science translational medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "345",
}